Tanja Obradovic, Oncology Medical Strategy Advisor at Mercurial AI, shared a post on LinkedIn about a recent article by Erin P. Balogh et al. published in JCO Oncology Practice:
“Where are we on access to cancer clinical trials in the United States in 2025?
Far from optimal with only 7% of cancer patient population participating in trials. Just published article by American Society of Clinical Oncology (ASCO) as special report captures current state of barriers facing cancer patients as well as research community.
Very comprehensive update for all stakeholders including Pharma, Biotech and CROs. Overcoming barriers will be critical action in the future in order to deliver benefits at the bedside of rapidly evolving and expanding new cancer drug development efforts.”
Title: ASCO State of Cancer Care in America Special Report 2025: Access to Cancer Clinical Trials in the United States
Authors: Erin P. Balogh, Laura A. Levit, Joseph M. Unger, Melissa K. Accordino, David D. Chism, M. Kelsey Kirkwood, Helen M. Parsons, Manali I. Patel, Jeffery M. Peppercorn, Blase N. Polite, Mina S. Sedrak, Priyanka Sharma, Ishwaria M. Subbiah, Jennifer S. Temel, K. Robin Yabroff, Raymond U. Osarogiagbon
Read the Full Article on JCO Oncology Practice
More posts featuring Tanja Obradovic.